Salt Lake City, Utah – February 13, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it has been invited to be a featured speaker to present its rapid response to the new coronavirus (Covid-19) global health concern, as well as its multiplex PCR solutions for mosquito-borne diseases, at the 3rd International Conference on Zika Virus and Aedes Related Infections. The conference will take place on February 13-16, 2020 in Washington D.C.

The Company will report how its proprietary design platform allowed Co-Diagnostics scientists to work quickly in response to the threat of the new strain of coronavirus. In addition to its work on coronavirus, the Company will showcase its infectious disease initiative, which incorporates its vector control solutions that it began commercializing in 2019. Co-Diagnostics Vector Smart™ assays include multiplex polymerase chain reaction (PCR) tests for Zika/dengue/chikungunya, and West Nile/St. Louis encephalitis/eastern equine encephalitis, among others. The Company also offers laboratory equipment and training packages, and has been marketing and selling its products to mosquito abatement districts across the country.

Co-Diagnostics Logix Smart™ diagnostics for Aedes mosquito-borne diseases include a CE-marked multiplex PCR assay for Zika/dengue/chikungunya. According to the World Health Organization, the global incidence of dengue alone has grown dramatically in recent decades. About half of the world’s population is now at risk, with an estimated 390 million infections each year.

Brent Satterfield, Chief Science Officer (CSO) and founder of Co-Diagnostics, remarked “Our ability to respond quickly in the face of an emergency is made possible thanks to the diligent work of Co-Diagnostics researchers and scientists, and their ability to apply our design platform to address global health concerns.

“However, in the time that the novel strain of coronavirus has captured the world’s attention, thousands more have continued to become infected, suffer, and even die from mosquito-borne illnesses that are often unknown in the developed world until outbreaks occur. Our catalog of highly-specific assays includes multiplex solutions for both vector control as well as in vitro diagnostics for human testing, and I am pleased to be able to present the quality of our technology to the dedicated, multi-disciplinary participants at this conference.”

The Company’s presentation is scheduled to take place on Saturday, February 15th at 12:45 PM, and will be conducted jointly by its CSO and Head of International Sales.

About Co-Diagnostics, Inc.: 

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. 

Forward-Looking Statements 

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.  Forward-looking statements in this release may include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in certain verticals or markets, (iv) capital resources and runway needed to advance the Company’s products and markets, (v) increased sales in the near-term, (vi) flexibility in managing the Company’s balance sheet, (vii) anticipation of business expansion, and (viii) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances.  Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.  

Company Contact:
Andrew Benson
Co-Diagnostics Investor Relations
Media Contact:
Jennifer Webb
Coltrin & Associates, Inc